New drug duo targets tough bile duct cancer after standard treatment fails
NCT ID NCT06938321
Summary
This study is testing the safety and effectiveness of a new two-drug combination (AK130 + AK112) for people with advanced bile duct cancer that has worsened after initial treatment. The first part finds the safest dose, and the second part sees how well the drugs work together. It aims to control the cancer and extend life for patients with limited options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.